NEW YORK (GenomeWeb News) – Cancer Genetics again lowered the amount it expects to raise in its pending initial public offering.
In a Form S-1/A filed with the US Securities and Exchange Commission on Monday, the Rutherford, NJ-based firm said that it expects to offer 1.85 million shares of stock in its IPO at a price of between $10 and $12 per share.
At the midpoint price of $11 per share, net proceeds from the offering is estimated at $16.3 million, Cancer Genetics said. If the offering's underwriters, Aegis Capital and Feltl and Co., exercise their over-allotment option, the net proceeds would rise to about $19.2 million, it added.
The company effected a one-for-two reverse stock split on February 8, and a one-for-2.5 reverse stock split on March 1.
If approved, Cancer Genetics' stock would list on Nasdaq under ticker symbol "CGIX".
Proceeds from the IPO would be used to repay "certain outstanding indebtedness"; fund R&D and regulatory submissions, as well as potential product launches and collaboration; hire additional sales and marketing staff; fund Cancer Genetics' joint venture with the Mayo Foundation for Medical Education and Research to develop oncology diagnostic services and tests using next-generation sequencing; and fund ongoing operations and business expansion, the company said.
The company also disclosed its earnings for 2012 in its SEC document. For full-year 2012 it took in $4.3 million in revenues, up 43 percent from $3.0 million in 2011.
Its R&D expenses were essentially flat at $2.1 million, while its SG&A costs were down 2 percent to $5.9 million from $6.0 million.
Cancer Genetics' net loss for the year was $6.7 million, or $10.55 per share, compared to a net loss of $19.9 million, or $15.61 per share, in 2011.
Last week, the firm announced it received CLIA and New York State approval for the clinical use of its mature B-cell neoplasm array to assist clinicians in the diagnosis and prognosis of diffuse large B-cell lymphoma.